The Equine Encephalitis drugs in development market research report provides comprehensive information on the therapeutics under development for Equine Encephalitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Equine Encephalitis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Equine Encephalitis and features dormant and discontinued products.
GlobalData tracks 14 drugs in development for Equine Encephalitis by 13 companies/universities/institutes. The top development phase for Equine Encephalitis is preclinical with seven drugs in that stage. The Equine Encephalitis pipeline has nine drugs in development by companies and five by universities/ institutes. Some of the companies in the Equine Encephalitis pipeline products market are: Defender Pharmaceuticals, US Army Medical Research & Materiel Command and Auro Vaccines.
The key targets in the Equine Encephalitis pipeline products market include Eastern Equine Encephalitis Virus Envelope Glycoprotein E1, Eastern Equine Encephalitis Virus E2 Glycoprotein (E2), and Glycoprotein.
The key mechanisms of action in the Equine Encephalitis pipeline product include Bacterial Cell Membrane Disruptor with one drug in Preclinical. The Equine Encephalitis pipeline products include eight routes of administration with the top ROA being Subcutaneous and five key molecule types in the Equine Encephalitis pipeline products market including Small Molecule, and Subunit Vaccine.
Equine Encephalitis overview
Eastern Equine Encephalitis (EEE) is a rare but serious viral disease that affects humans and horses, caused by the Eastern Equine Encephalitis virus (EEEV), belonging to the Togaviridae family. The virus is primarily transmitted through the bite of infected mosquitoes, belonging to the Culiseta melanura species. The symptoms of EEE in humans can range from mild flu-like symptoms to more severe cases involving encephalitis (inflammation of the brain), high fever, headache, stiff neck, and lack of energy.
For a complete picture of Equine Encephalitis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
